Navigation Links
Synvista Therapeutics Highlights Newly Published Data Demonstrating the Value of Haptoglobin Genotype Testing In People with Diabetes
Date:3/5/2008

an inexpensive therapy, Vitamin E, to their statin therapy."

In the placebo-controlled ICARE study, more than 3,000 patients were tested for Haptoglobin phenotype, and the 801 patients who had the Hp2-2 phenotype who were also taking statins were randomized to receive either natural source Vitamin E (400 IU daily) or placebo. Results demonstrated a dramatic reduction in the event rate of those taking combination therapy of Vitamin E and statins compared with statin treatment alone (1.3 percent compared with 4.1 percent, respectively, p=0.017) after 600 days.

About the ICARE Study

The ICARE (Israel Cardiovascular events Reduction with Vitamin E) study is a prospective, randomized placebo controlled trial of Vitamin E therapy in individuals with diabetes mellitus and the Haptoglobin 2-2 genotype. The study was conducted in conjunction with the Clalit Health Service in Israel by Andrew Levy, M.D., Shany Blum, M.D., Uzi Milman, M.D., et. al. of the Technion Faculty of Medicine, Technion Institute of Technology, Haifa, Israel. The population-based study of more than 3,000 individuals age 55 and older with diabetes were tested for Hp type and followed for two years in a registry. The study was halted in 2007 based on a 50 percent decrease in cardiovascular events in patients with Hp 2-2 taking Vitamin E, as the primary endpoints had been met.

About Haptoglobin 2-2

The Hp protein is polymorphic in humans, occurring with two alleles, 1 and 2, existing at the Hp genetic locus. Three phenotypes linked to the three genotypes, Hp 1-1, Hp 1-2 and Hp 2-2, can be identified using an ELISA assay. In multiple independent prospective longitudinal studies of more than 20,000 individuals, it has been established that the Haptoglobin genotype is an independent risk factor for cardiovascular disease, with a specific relationship to patients with diabetes mellitus. After accounting for conventional cardiovascular risk factors and diabetes characteristics
'/>"/>

SOURCE Synvista Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Synvista Therapeutics to Present at the 10th Annual BIO CEO & Investor Conference
2. Synvista Therapeutics to Develop Topical Formulation of ALT-2074 for the Treatment of Psoriasis
3. Synvista Therapeutics to be Featured on Wallst.net
4. Synvista Therapeutics to Present at the BIO InvestorForum 2007
5. Cell Therapeutics, Inc. to Hold Conference Call to Update on Recent Transactions and Upcoming Milestones
6. M. Scott Harris, M.D., Joins Ocera Therapeutics, Inc., as Chief Medical Officer
7. CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financial Results
8. TorreyPines Therapeutics to Present at Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
9. Hsiao Dee Lieu, M.D., F.A.C.C. Named VP of Clinical Research of Nile Therapeutics
10. The Diabetes Series 2008: Experts Speak About Developing Diabetes Therapeutics
11. CV Therapeutics Announces Presentations at the American College of Cardiology 57th Annual Scientific Session
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... and HONG KONG , ... rare disease therapeutics enterprise, announced today that rare disease ... company as vice president, research. Dr. McKew brings more ... key leadership positions at the National Institutes of Health, ... acquisition by Wyeth). Dr. McKew will lead aTyr,s efforts to ...
(Date:10/20/2014)... GUELPH, ON , Oct. 20, 2014 /PRNewswire/ - BIOREM Inc. ... totalling $1.7 million which brings Q3 orders to $5.8 million and ... odour control projects in North America and ... "We continue to bid new projects at record levels," said ... values were higher at the end of Q3 than they have ...
(Date:10/20/2014)... October 20, 2014 Earle ... LLC, announced today that Ellen Teplitzky, an experienced ... for the pharmaceutical industry, has joined the firm ... its legal services practice. NDA Partners provides ... witness and testimony, to top law firms and ...
(Date:10/19/2014)... The Asia-Pacific Bromine Market report defines ... analysis and forecast of revenue. , Browse through ... report, to get an idea of the in-depth ... the segmentation in the Asia-Pacific bromine market, and ... , http://www.micromarketmonitor.com/market/asia-pacific-bromine-6741503144.html , Bromine is a ...
Breaking Biology Technology:aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3NDA Partners Appoints Ellen Teplitzky, JD as Director of its Legal Services Practice 2The Asia-Pacific Bromine Market is estimated to grow to $4,080.1 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific Bromine Market is estimated to grow to $4,080.1 million by 2018 - New Report by MicroMarket Monitor 3
... will be Centerpiece to Expansion of ... Radiation Oncology Facility, ... ), a global leader in the field of radiosurgery,today announced ... Robotic Radiosurgery System to further expand treatment,offerings for its nationally ...
... 24 United,Therapeutics Corporation (Nasdaq: UTHR ) ... quarter financial results before the open of market,on ... host a half-hour teleconference on Thursday,July 31, 2008, ... accessible,by dialing 1-800-603-1777, with international callers dialing,1-706-679-8129. A ...
... VEDBAEK, Denmark, July 24 Frost & Sullivan,has announced ... 2008 Growth,Strategy Leadership Award in the molecular diagnostic market. ... the molecular diagnostic,market., Exiqon was selected for this ... leader in the field of in vitro therapy selection,testing ...
Cached Biology Technology:St. Luke's Episcopal Hospital to Add CyberKnife System to Treatment Offerings 2St. Luke's Episcopal Hospital to Add CyberKnife System to Treatment Offerings 3St. Luke's Episcopal Hospital to Add CyberKnife System to Treatment Offerings 4Exiqon Receives the 2008 Frost & Sullivan Growth Strategy Leadership Award 2Exiqon Receives the 2008 Frost & Sullivan Growth Strategy Leadership Award 3
(Date:10/16/2014)... Cancer constantly wages war on the human body. ... a stalemate. In pancreatic cancer, this stalemate—known as ... becoming aggressively malignant, a phenomena that is poorly ... in the laboratory of Salvatore Torquato, a Professor ... the conditions surrounding tumor dormancy and the switch ...
(Date:10/16/2014)... conventional thinking on how the bowel lining develops and, ... bowel cancer starts. , The researchers produced evidence that ... ,crypts, that are a feature of the bowel lining, ... cancer development, a controversial finding as scientists are still ... imaging technologies, Dr Chin Wee Tan and Professor Tony ...
(Date:10/16/2014)... – Post-menopausal women experienced improvements in vaginal atrophy, ... genital bleeding, after 12 weeks of daily 10 ... germ-based nutritional supplement previously shown to help relieve ... pilot study reported in a poster at the ... , "These data documented improved vaginal epithelium, ...
Breaking Biology News(10 mins):Modeling tumor dormancy 2Cryptic clues drive new theory of bowel cancer development 2S-equol supplements associated with improved measures of reproductive health in postmenopausal women 2
... A variety of end products including jet fuel, gasoline, ... existing refineries and combinations of coal and refinery by-products, ... idea is based on the coal-to-jet fuel work that ... Caroline E. Burgess Clifford, research associate at Penn State,s ...
... tiny, spherical nanogels that uniformly release encapsulated carbohydrate-based ... transfer radical polymerization (ATRP), which will ultimately enable ... the target and to dispense the drug in ... 200 nanometers in diameter possess many unique ...
... Pacific Northwest National Laboratory,have discovered a way to ... creation of a portable biosensor that can address ... nerve agents, the need to quickly distinguish between ... The sensor components resemble a pregnancy test ...
Cached Biology News:Coal-based fuels and products hit the refinery 2Carnegie Mellon scientists develop nanogels that enable controlled delivery of carbohydrate drugs 2Truly sick or simply scared? 2
[14C]Polyethylene glycol 4000, 9.25 MBq, 250 uCi. Aqueous solution containing 3% ethanol, sterilized. 370-740 MBq/g, 10-20 mCi/g.1.85 MBq/ml, 50 uCi/ml. Category: Radiochemicals &Radiation Safety, ...
Request Info...
interferon-related developmental regulator 2...
PlusOne EDTA, disodium salt, 100 g. Category: Electrophoresis Systems & Standards & Reagents, Electrophoresis Standards and Reagents, Buffers....
Biology Products: